ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, the company is headquartered in Singapore and has offices in Taiwan and China.
Cyborg Score Rationale
The company was delisted from Nasdaq in July 2024 due to non-compliance with bid price and stockholders' equity requirements, and the company's board determined not to appeal the delisting decision. The company faces significant capital constraints and limited cash runway as a clinical-stage biotech without active market trading.
Top Insights
Delisted from NASDAQ (July 2024) due to failure to meet listing standards; now trades over-the-counter
Lead candidate eblasakimab showed positive Phase 2b data in atopic dermatitis; Phase 2 trial (TREK-DX) ongoing
Secondary program farudodstat in early-stage development for alopecia areata
Strategic focus on Asia-prevalent diseases with orphan indication applications in US/EU markets
Named Competitors
Dupilumab — IL-4 receptor antibody for atopic dermatitis and other allergic conditions
Tralokinumab — IL-13 antibody for atopic dermatitis
JAK Inhibitors — Oral immunosuppressants for alopecia areata and dermatologic conditions
Recent Developments
(July 2024) Delisted from Nasdaq after failing to meet $1.00 bid price and $2.5M stockholders' equity requirements
(2024) Reported positive Phase 2b topline data for eblasakimab in moderate-to-severe atopic dermatitis